**Supplementary Fig. 6. Forest plot of SOF-based DAA with or without RBV for the treatment of patients with decompensated hepatitis C cirrhosis.** There was no statistically significant difference in the SVR in groups treated with a SOF/DAA regimen with RBV and without RBV: 83.8% (95% CI: 76.8–89.8) vs. 84.9% (95% CI: 81.7–87.9), *p*=0.7634. SOF, sofosbuvir; RBV, ribavirin; DAA, direct-acting antiviral; SVR, sustained virologic response.

